Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Language : Français
Active substance : piroxicam
Active substance : riboflavine
Active substance : hydrocortisone
Active substance : phosphate
Active substance : hyaluronidase
Producer : industriels

Topic

Economics and public health (1)
Plus ...
- Ethics (1)
Diagnostic and therapeutic techniques (1)
Plus ...
- Esthetics (1)
Quality of care and patient safety (1)
Plus ...

Drugs, devices and medical acts (1)
Plus ...
- Health technology assessment (1)

inconnu (1)
industriels (1)

Français (1)

Active substance

acide ascorbique (1)
alcool (1)
aminophylline (1)
artichaut (1)
azathioprine (1)
biotine (1)
calcitonine de saumon (1)
chlore actif (1)
colchicine (1)
fructose (1)
galactose (1)
huile de ricin (1)
hyaluronidase (1)
hydrocortisone (1)
iode (1)
mannitol (1)
minoxidil (1)
pentoxifylline (1)
phosphate (1)
piroxicam (1)
prednisolone (1)
pyridoxine (1)
riboflavine (1)
sodium (1)
thiocolchicoside (1)
zinc (1)

Drugs, devices and medical acts - 1 result

Assessment of the risks associated with aesthetic mesotherapy practices

Health technology assessment - Posted on 22/7/2014

Download document

Add to my selection

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

WGe8FfGsDKt21CFc